Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

Part of paid clinical trials in San Francisco, California.

Sponsor
HBC Immunology Inc
Study ID
NCT06726785
Status
Recruiting
Apply to this trial

Conditions

  • Restless Leg Syndrome (RLS)

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Study Details

The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in RLS. The dopamine agonist drugs to be included in this study are: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), Bromocriptine (Parlodel). Specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. This research could provide insight into changes in dopaminergic gene expression associated with Augmentation Syndrome (AS) which occurs after long term dopamine agonist treatment in RLS patients.

Key Dates

Start date
Jul 1, 2025
Status verified
Sep 2025
Primary completion
Dec 30, 2025
Completion
Feb 27, 2026

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

To analyze the effect of duration of dopamine agonist treatments for changes in dopaminergic genes expression using nasal epithelial cells. [ Time Frame: 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Alethios IncSan FranciscoCalifornia94109
Zeenia Framroze, MA
[email protected]
650-206-8006

Find similar trials in San Francisco, CA

By research site
Alethios Inc· San Francisco, CA

Related Studies